Format

Send to

Choose Destination
Gynecol Oncol. 2009 Oct;115(1):135-137. doi: 10.1016/j.ygyno.2009.06.012. Epub 2009 Jul 3.

Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

Author information

1
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
2
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada.
3
Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
4
Department of Medicine and Genetics, University of Pennsylvania, Philadelphia, PA, USA.
5
Clinical Genetics and Gynecology Services, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA.
6
Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, NE, USA.
7
Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
8
Beth Israel Deaconess Hospital, Boston, MA, USA.
9
Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
10
Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada. Electronic address: steven.narod@wchospital.ca.

Abstract

OBJECTIVE:

BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen treatment is associated with an increase in the subsequent risk of ovarian cancer among women with a BRCA1 mutation.

METHODS:

A matched case-control study was performed. Cases were 154 women with ovarian cancer and a previous history of breast cancer. Controls were 560 women with no ovarian cancer and a history of breast cancer. All cases and controls carry a deleterious BRCA1 mutation. Cases and controls were matched for year of birth, age at diagnosis of breast cancer and country of residence. The effect of tamoxifen treatment on the risk of subsequent ovarian cancer was estimated using conditional logistic regression.

RESULTS:

The unadjusted odds ratio for ovarian cancer, given previous tamoxifen treatment was 0.89 (95% CI 0.54-1.49, p=0.66). After adjusting for other treatments, the odds ratio was 0.78 (95% CI 0.46-1.33, p=0.36).

CONCLUSION:

Tamoxifen treatment for breast cancer does not appear to increase the risk of ovarian cancer in BRCA1 mutation carriers.

PMID:
19577280
PMCID:
PMC3756313
DOI:
10.1016/j.ygyno.2009.06.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center